Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Targeting 20-HETE producing enzymes in cancer – rationale, pharmacology, and clinical potential
Authors Alexanian A, Sorokin A
Received 11 December 2012
Accepted for publication 17 February 2013
Published 26 March 2013 Volume 2013:6 Pages 243—255
DOI https://doi.org/10.2147/OTT.S31586
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Anna Alexanian, Andrey Sorokin
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Abstract: Studies demonstrate that lipid mediator 20-Hydroxyeicosatetraenoic acid (20-HETE) synthesis and signaling are associated with the growth of cancer cells in vitro and in vivo. Stable 20-HETE agonists promote the proliferation of cancer cells, whereas selective inhibitors of the 20-HETE-producing enzymes of the Cytochrome (CYP450)4A and CYP4F families can block the proliferation of glioblastoma, prostate, renal cell carcinoma, and breast cancer cell lines. A recent observation that the expression of CYP4A/4F genes was markedly elevated in thyroid, breast, colon, and ovarian cancer further highlights the significance of 20-HETE-producing enzymes in the progression of different types of human cancer. These findings provide the rationale for targeting 20-HETE-producing enzymes in human cancers and set the basis for the development of novel therapeutic strategies for anticancer treatment.
Keywords: 20-hydroxyeicosatetraenoic acid, CYP4A, CYP4F, HET0016, eicosanoids
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.